Provided By GlobeNewswire
Last update: Apr 24, 2024
Q1 2024 revenue and non-IFRS adjusted EPS* above the high end of guidance ranges;
2024 full-year outlook raised
119.25
-5.77 (-4.62%)
Find more stocks in the Stock Screener
A fundamental analysis of (NYSE:CLS): Why Quality-Oriented Investors Should Consider NYSE:CLS.